



Friday, September 11

Time	Topic
10:00 – 10:20 AM Central Time (CT)	<p>Welcome Ralph DeVitto, <i>ABTA President & CEO</i></p> <p>Jim Reilly, <i>ABTA Board Chair</i></p> <p>Mark R. Gilbert, MD <i>Center for Cancer Research, National Cancer Institute, National Institutes of Health</i> <i>ABTA National Conference Co-Chair</i></p> <p>Jean Arzbaecher, RN, APN, CNRN <i>The University of Illinois at Chicago</i> <i>ABTA National Conference Co-Chair</i></p>
10:20 – 10:50 AM CT	<p>ABTA Session: Who We Are, What We Offer & How to Get Involved Introductions by: Brandon Starkoff, <i>ABTA Vice Chair</i></p> <p>Nicole Willmarth, PhD, <i>ABTA Chief Mission Officer</i></p> <p>Alicia Morris, <i>ABTA Director, National Volunteers</i></p> <p>Learn more about invaluable ABTA resources and programs offered to patients, caregivers and families that can provide support along the trajectory of a brain tumor diagnosis.</p>
10:50 – 10:55 AM CT	<p>Break featuring:</p> <p><u>Sponsor:</u> Northwestern Medicine</p> <p>Multi-disciplinary Team Approach to Treating Brain Tumors: A Brain Tumor Patient Story Roger Stupp, MD; Rimas Lukas, MD; Virginia B. Hill, MD; Maciej S. Lesniak, MD, MHCM, FAANS; Daniel J. Brat, MD, PhD; John A. Kalapurakal MD, FACR, FASTRO; Vinai Gondi, MD; Chris Balmaceda, LCSW</p>
10:55 – 11:25 AM CT	<p>Brain Tumor Network: Guiding and Empowering Patients and Caregivers Presenting Sponsor: Sontag Foundation and Brain Tumor Network</p> <p>Stephanie Gebhardt, DNP, APRN Eden C. Mock, MSW, OPN-CGd</p> <p>Patient navigation is still considered a relatively new term in the health care industry, measured by metrics and tools. This session explores the positive impacts of Brain Tumor Navigation through the metric that matters most: the patient experience.</p>



11:25 – 11:30 AM CT

Break featuring:

Sponsor:

Orbus Therapeutics

STELLAR Study: A Phase 3 Trial for Patients with Recurrent Anaplastic Astrocytoma

Kartik Aysola, MD

11:30 AM – 12:15 PM CT

Bench to Bedside: How Science Impacts Brain Tumor Patient Care

Shawn Hervey-Jumper, MD, FAANS, *University of California San Francisco*

Understand the importance of basic science research and how medical professionals apply this knowledge to brain tumor treatment and care.

12:15 – 1:00 PM CT

Lunch Session featuring:

Sponsors:

Monteris Medical

The NeuroBlate System for Brain Tumors: A minimally invasive laser ablation procedure for brain tumors

Marty Emerson, CEO

Cleveland Clinic

Care and Treatment of Primary Brain Tumors: A multi-disciplinary approach to Primary Brain Tumors

Manmeet Ahluwalia, MD

GT Medical Technologies

GammaTile Therapy: A Head Start In The Fight Against Brain Tumors: Surgically Targeted Radiation Therapy For Brain Tumors

Kory Thomas, *Regional Sales Director*

Research updates:

Cytomegalovirus Oncomodulation of the Glioblastoma Tumor Environment

Christine O'Connor, PhD, *Cleveland Clinic*

Validation of Diffusion MRI as a Predictive Imaging Biomarker for Anti-VEGF Therapies in Recurrent Glioblastoma

Benjamin Ellingson, PhD, *University of California, Los Angeles*

Sponsors:

Advocate Children's Midwest Brain Tumor Center

A Multidisciplinary Approach To Pediatric Patient Care

John Ruge, MD, *Director of Pediatric Neurosurgery*

Agios Pharmaceuticals

Introduction to Agios: Our Research in Low Grade Glioma

Susan Pandya MD, *Vice President, Clinical Development*



1:00 – 1:45 PM CT	<p>The Practical Approaches to Diagnosis & Treatment of Brain Tumors Stefania Maraka, MD, <i>University of Illinois at Chicago</i></p> <p>Immerse in the understanding of diagnosis and treatment options for brain tumors, including recognizing the difference between primary and secondary brain tumors and current treatment options.</p>
1:45 – 1: 50 PM CT	<p>Break featuring:</p> <p><i>Research update:</i> Repurposing Remyelination Drugs for Oligodendroglioma Therapeutics Yiping He, PhD, <i>Duke University Medical Center</i></p>
1:50 – 2:35 PM CT	<p>Immunotherapy: Challenges and Opportunities for Brain Tumors Peter Fecci, MD, PhD, <i>Duke University Medical Center</i></p> <p>Learn about the current state of immunotherapy, its impact in brain tumor treatment, and the path to progress for treating primary and metastatic brain tumors.</p>
2:35 – 2:40 PM CT	<p>Break featuring:</p> <p><i>Research update:</i> Unraveling Regulatory T Cell-Dependent Anti-Tumor Mechanisms in Brain Metastasis Wei Du, MD, PhD, <i>Virginia Commonwealth University</i></p>
2:40 – 3:10 PM CT	<p>Joel A. Gingras Jr. Award Presentation: Introductions by: Jim Reilly, <i>ABTA Board Chair</i></p> <p>Christian Gingras, <i>Vice President, Joel A. Gingras, Jr. Memorial Foundation</i></p> <p>Priscilla Brastianos, MD, <i>Massachusetts General Hospital, Harvard Medical School</i></p> <p>Since 2011, the ABTA has awarded the Joel A. Gingras Jr. Award to recognize an individual, organization or group that has made significant contributions to the Association’s mission through philanthropy, advocacy, research or patient care.</p>
3:10 – 3:50 PM CT	<p>Keynote Session: Maria Menounos: Embodying the Role of Caregiver & Patient</p> <p>Interviewed by: Mindee Plugues, <i>ABTA Chair, Mission Committee</i></p> <p>Emmy® Award-winning journalist, author, actress and three-year brain tumor survivor Maria Menounos shares her personal experience, going from caregiver to patient. Maria will share personal insights on juggling public life while caring for her mother who was diagnosed with a glioblastoma brain tumor, and then turning her learnings inward as a patient and survivor of a meningioma brain tumor. Maria’s story shares encouragement and insights for others experiencing the brain tumor journey.</p>



American
Brain Tumor
Association®

2020 NATIONAL CONFERENCE

3:50 – 4:00 PM CT

Closing Remarks

Introductions by: Mindee Plugues, *ABTA Chair, Mission Committee*

Susan Kramer, *ABTA Co-Founder, Honorary Board Member*

4:00 – 4:45 PM CT

Optional: Social Hour for Current and Future Volunteers

Alicia Morris, *ABTA Director, National Volunteers featuring ABTA Volunteers*

Join a fun, interactive hour with ABTA volunteers from all across the country! We will discuss all the great ways volunteers can spread awareness and get involved in their communities.



Saturday, September 12

Time	Topic
10:00 – 10:10 AM Central Time (CT)	<p>Welcome Ralph DeVitto, <i>ABTA President & CEO</i></p> <p>Don and Gail Segal, <i>ABTA Honorary Board Members</i></p>
10:10 – 11:20 AM CT	<p>Brain Tumor Board</p> <p>Listen in as a multi-disciplinary panel of expert clinicians simulate the review of brain tumor cases to determine the best course of treatment for patients.</p> <p><u>Facilitator:</u> Mark R. Gilbert, MD, <i>Center for Cancer Research, National Cancer Institute, National Institutes of Health</i></p> <p><u>Panelists:</u> Evanthia Galanis, MD, <i>Mayo Clinic</i> Shawn Hervey-Jumper, MD, FAANS, <i>University of California San Francisco</i> Jason T. Huse, MD, PhD, MD, <i>Anderson Cancer Center</i> Vijay Ramaswamy, MD, PhD, FRCPC, <i>Hospital for Sick Children, University of Toronto</i> Jennifer Yu, MD, PhD, <i>Cleveland Clinic</i></p>
11:20 – 11:25 AM CT	<p>Break featuring:</p> <p><u>Research update:</u> NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma Zeng-jie Yang, MD, PhD, <i>The Research Institute at Fox Chase Cancer Center</i></p>
11:25 – 12:10 PM CT	<p>The Importance of Patient Outcomes Assessments in Determining Optimal Treatment</p> <p>Terri S. Armstrong, PhD, ANP-BC, FAAN, FAANP <i>Center for Cancer Research, National Cancer Institute</i></p> <p>Assessing a patient’s progress against the initial treatment plan (patient outcomes) is an essential step in care. This session covers the needs and benefits of evaluating outcomes for the patient, scientific progress and development of new treatments.</p>
12:10 – 1:10 PM CT	<p>Lunch Break featuring:</p> <p><u>Meet the ABTA Board of Directors:</u> Jim Reilly, <i>Chair</i> Brandon Starkoff, <i>Vice Chair</i> Carla Varner, <i>Secretary</i> Susannah Davis, <i>Director</i></p>



Bob Kruchten, *Chair, Development Committee*
Jacqueline Lemke, *Director*
Mindee Plugues, *Chair, Mission Committee*

Meet the ABTA Board Members and hear why they are involved with ABTA.

Sponsors:

Karyopharm Therapeutics

Selinexor in GBM: XPORT-GBM-029. A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Jatin Shah MD, CMO

NorthShore University Health System

NorthShore Neurological Institute’s Brain Tumor Program: Procedures, Innovations, Clinical Trials, and a Multispecialty Team

Ryan Merrell, MD

Research updates:

A Novel Pressure-Reducing Therapy to Abrogate Tumor Invasiveness and Immune Infiltration in Glioblastoma

Hanna Sabelstrom, PhD, *University of California, San Francisco*

Microcircuit Platform to Screen Ion Channel Blockers for Medulloblastoma

Min Tang-Schomer, PhD, *The Jackson Laboratory for Genomic Medicine*

Programming Tumor-Clearing Macrophages with Targeted Gene Therapy

Fan Zhang, PhD, *Fred Hutchinson Cancer Research Center*

Sponsors:

Northwest Biotherapeutics

DCVax® Personalized Immune Therapies: Explanation of what dendritic cell therapies (such as DCVax) are, how they work and how they are different from other kinds of treatments for Glioblastoma

Ms. Linda Powers, *CEO*

Elekta

Zero in on Brain Metastases: Leksell Gamma Knife Icon

Sean Looney, *Director of Business Marketing Neuroscience*

Novocure

Thought Leader Liaison: An FDA Approved treatment for Glioblastoma

Rena Adams, *Thought Leader Liaison*

1:10 – 1:55 PM CT

Clinical Trials: A Primer

Mark R. Gilbert, MD, *Center for Cancer Research, National Cancer Institute, National Institutes of Health*

Participation in clinical trials can offer patients and families access to novel brain tumor treatments. This session offers attendees ground-level strategies in considering clinical trials.



<p>1:55 – 2:20 PM CT</p>	<p>Clinical Trials: Panel Discussion with Experts</p> <p>This panel has been designed to allow world-renowned clinical study experts to give their perspectives on the current state and future directions of clinical research for patients with brain and spinal cord tumors. Importantly, hear from the patient perspective from a patient who has participated in brain tumor clinical trials.</p> <p><u>Facilitator:</u> Mark R. Gilbert, MD, <i>Center for Cancer Research, National Cancer Institute, National Institutes of Health</i></p> <p><u>Panelists:</u> Terri S. Armstrong, PhD, ANP-BC, FAAN, FAAN, <i>Center for Cancer Research, National Cancer Institute</i> Jean Arzbaecher, RN, APN, CNRN, <i>The University of Illinois at Chicago</i> Peter Fecci, MD, PhD, <i>Duke University Medical Center</i> Evanthia Galanis, MD, <i>Mayo Clinic</i> Donna Van Ryn, <i>clinical trial patient</i></p>
<p>2:20 – 2:25 PM CT</p>	<p>Break featuring:</p> <p><u>Research update:</u> Radiogenomic Prediction of Pediatric Medulloblastoma Molecular Subgroup Kristen Yeom, MD, <i>Stanford University</i></p>
<p>2:25 – 3:10 PM CT</p>	<p>Holistic Management of Brain Tumor Symptoms Roy E. Strowd III, MD, Med, MS, <i>Wake Forest School of Medicine</i></p> <p>Learn about common brain tumor symptoms during the phases of treatment as well as complementary approaches and interventions such as cannabis, acupuncture and other therapies.</p>
<p>3:10 – 3:15 PM CT</p>	<p>Break featuring:</p> <p><u>Research update:</u> An Investigation of Telomere Maintenance Mechanism in ATRX Mutant Gliomas Lee Wong, PhD, <i>Monash University</i></p>
<p>3:15 – 4:00 PM CT</p>	<p>Caring for The Caregiver Jean Arzbaecher, RN, APN, CNRN, <i>The University of Illinois at Chicago</i></p> <p>A brain tumor diagnosis is a life-changing event, not only for the patient, but also for family members and loved ones. This session will explore the many roles of caregivers and identify strategies and resources to facilitate the process of caregiving.</p>



4:00 – 4:05 PM CT

Break featuring:

Research update:

Targeting TLR2 in EGFR/EGFRvIII+ Glioblastoma

Zhenyi An, PhD, *University of California, San Francisco*

4:05 – 4:50 PM CT

Living with a Brain Tumor: Patient and Caregiver Panel

Learn key strategies and approaches to navigate your brain tumor journey or that of your loved one in this lively and interactive brain tumor patient and caregiver panel. Get ideas for how to cope and where to find resources and support.

Facilitator: Jean Arzbaecher, RN, APN, CNRN, *The University of Illinois at Chicago*

Patient and Caregiver Panelists:

Donna and Paul Van Ryn

Aisha Khalid Khan and Kholā Shuaib

Steffanie and Scott Flack

4:50 – 5:00 PM CT

Closing Comments & Adjournment

Ralph DeVitto, *ABTA President & CEO*

Jim Reilly, *ABTA Board Chair*